POLE mutation analysis may not be necessary in typical low‐grade endometrioid carcinomas since POLE mutations are not common in this group and these neoplasms would not qualify for adjuvant therapy unless they are advanced stage at diagnosis. This evidence concerns the gene POLE and neoplasm.